eMed is the gold standard in clinically managed GLP-1 programs for employers. At the core is a fundamental reality: GLP-1s are among the most significant therapeutic advances of our time, but their impact is only realized when patients stay on treatment. By achieving more than 90% member adherence, more than double the industry norm, eMed's program delivers what others cannot: employees who stay the course and see real results, including an average weight loss of 21 pounds, with 99% seeing improvement in at least one key biomarker within six months.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/26/26	$200,000,000	Venture	8VC Antonio Gracias AON Ara Cohen Jeff Aronin Linda Yaccarino R.J. Melman Tim Ricketts Tom Brady	$2,000,000,000